Rapid effect of inhaled ciclesonide in asthma: A randomized, placebo-controlled study

Chest

Volumn 134, Issue 4, 2008, Pages 740-745

  Erin, Edward M ^a   Zacharasiewicz, Angela S ^b   Nicholson, Grant C ^a   Tan, Andrew J ^a   Neighbour, Helen ^a   Engelstätter, Renate ^c   Hellwig, Michael ^c   Kon, Onn Min ^d   Barnes, Peter J ^e   Hansel, Trevor T ^a,f  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b WILHELMINEN HOSPITAL   (Austria)

^c Nycomed GmbH   (Germany)

^d ST MARY S HOSPITAL   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Airway hyperresponsiveness; Asthma; Ciclesonide; Nitric oxide; Sputum

Indexed keywords

ADENOSINE PHOSPHATE; CICLESONIDE; NITRIC OXIDE; PLACEBO;

ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THORAX PAIN; TOTAL LUNG CAPACITY; WHEEZING;

EID: 54249100556     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-2575     Document Type: Article

References (27)

1. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780-793
2. GINA. Global Initiative for Asthma. National Institutes of Health, National Heart, Lung and Blood Institute. 2005. Available at: www.ginasthma.com. Accessed October 5, 2007
3. van den Berge M, Polosa R, Kerstjens HA, et al. The role of endogenous and exogenous AMP in asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2004; 114:737-746
4. Dinakar C. Exhaled nitric oxide in the clinical management of asthma. Curr Allergy Asthma Rep 2004; 4:454-459
5. Kim CK, Hagan JB. Sputum tests in the diagnosis and monitoring of asthma. Ann Allergy Asthma Immunol 2004; 93:112-122; quiz 22-24, 84
6. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996; 153:454-457
7. Lanz MJ, Eisenlohr C, Llabre MM, et al. The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast. Ann Allergy Asthma Immunol 2001; 87:283-288
8. Spicuzza L, Polosa R. The role of adenosine as a novel bronchoprovocant in asthma. Curr Opin Allergy Clin Immunol 2003; 3:65-69
9. Luijk B, Kempsford RD, Wright AM, et al. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J 2004; 23:559-564
10. Dietzel K, Engelstätter R, Keller A. Ciclesonide: an on-site activated steroid. Prog Respir Res 2001; 31:91-93
11. Ukena D, Biberger C, Steinijans VW, et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther 2007; 20:562-570
12. Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 2006; 19:404-412
13. Derom E, van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005; 18:328-336
14. Engelstätter R, Escher A, Haefner D. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide [abstract]. Eur Respir J 2005; 26(suppl 49):255s
15. Taylor D, Jensen M, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 237-243
16. Kanniess F, Richter K, Bohme S, et al. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients in mild asthma. Pulm Pharmacol Ther 2001; 14:141-147
17. Djukanovic R, Sterk PJ, Fahy JV, et al. Standardised methodology of sputum induction and processing [abstract]. Eur Respir J Suppl 2002; 37:1s-2s
18. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am J Respir Crit Care Med 2006; 174:753-762
19. Wilson AM, Duong M, Pratt B, et al. Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients. Allergy 2006; 61:537-542
20. Phillips K, Oborne J, Lewis S, et al. Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. Thorax 2004; 59:26-30
21. Holgate ST, Arshad H, Stryszak P, et al. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. J Allergy Clin Immunol 2000; 105:906-911
22. Vathenen AS, Knox AJ, Wisniewski A, et al. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991; 143:1317-1321
23. Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am J Respir Crit Care Med 2001; 163:32-36
24. Jatakanon A, Kharitonov S, Lim S, et al. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999; 54:108-114
25. Ketchell RI, Jensen MW, Lumley P, et al. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5′-monophosphate in mild asthma. J Allergy Clin Immunol 2002; 110:603-606
26. Erin EM, Leaker BR, Zacharasiewicz AS, et al. Single dose topical corticosteroid inhibits IL-5 and IL-13 in nasal lavage following grass pollen challenge. Allergy 2005; 60:1524-1529
27. Parameswaran K, Inman MD, Watson RM, et al. Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers. Can Respir J 2000; 7:313-319